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1488activation prior to CAP should be considered as a
signiﬁcant limitation of the study that possibly con-
founds its results.
In addition, the editorial by Santos-Gallego and
Badimon (2) raises an important question regarding
the role of platelet aggregation as a risk factor or a
risk marker in these entities. However, platelet
aggregation was not assessed in the present study,
which utilized only soluble markers of platelet
reactivity Platelet activation is an ongoing and
continuous process that is better represented by
ex vivo markers, such as homotypic and heterotypic
platelet aggregation. The gold standard method for
estimation of heterotypic platelet aggregation is
considered the measurement of monocyte-platelet
aggregates (MPA) assessed by ﬂow cytometry. MPA
have been proven a robust and reproducible in vivo
marker of platelet activation (5), even in the clinical
setting (5), and could have been used in order to
assess more accurately the extend of platelet reac-
tivity and to understand the role of platelet func-
tion, and more than that, the role of antiplatelet
therapy.
In conclusion, a number of factors should be taken
into consideration before establishing a connection
between CAP, platelet activation, and MI. Platelets’
pathophysiological interplay between inﬂammation
and thrombosis suggested by in vitro studies needs
to be further investigated in well-designed clinical
studies with robust platelet activation markers.Eleni Gavriilaki, MD, MSc
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Myocardial Infarction in
Patients With PneumoniaAre Statins the Answer?In this population-based cohort study, Cangemi et al.
(1) found that increased platelet activation and
thromboxane overproduction was associated with
myocardial infarction in patients with pneumonia.
Moreover, they also suggested that aspirin alone was
insufﬁcient to inhibit thromboxane production.
Although, the study is observational in nature, it adds
to already accumulated evidence that suggests
increased cardiovascular events with infection and
sepsis (2). Statins with their anti-inﬂammatory and
antithrombotic effects may play a role in the treatment
of pneumonia and prevent associated cardiovascular
complications. Statins have been shown, not only to
inhibit thromboxane synthesis (3), but to also do so in
case of incomplete inhibition by aspirin (4). Statins
also decrease P-selectin and soluble CD40 ligand, both
of which play a role in atherosclerosis and consequent
cardiovascular events. Epidemiological evidence has
shown a beneﬁcial effect in the treatment of pneu-
monia (5). However, the available evidence is weak
because it is based on observational design. Given the
biological plausibility of the association, randomized
controlled trials are needed to deﬁne the role of statins
in the treatment of pneumonia and its associated
cardiovascular complications.*Abdur Rahman Khan, MD
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Establishing a Link?
Platelet Activation and Myocardial Infarction
in Patients With Pneumonia
Are Statins the Answer?We thank Dr. Gavrillaki and colleagues for the com-
ments related to our recent paper (1) demonstrating a
signiﬁcant association between in vivo platelet acti-
vation and myocardial infarction (MI) in 278 patients
affected by community-acquired pneumonia (CAP)
and suggesting a potential role for platelets in
precipitating coronary ischemia.
Dr. Gavrillaki and colleagues raise some issues that
need to be addressed. The authors question the pu-
tative interplay between infections and MI overall
because interventional trials with antibiotics failed to
show a reduction of MI. However, trials with antibi-
otics have serious clinical and methodological limi-
tations regarding dosages of the antibiotics, wide
variation in sample size and follow-up, and limited
use of antibiotics (essentially macrolides and ﬂuo-
roquinolone) (2). Furthermore, interventional trials
with antibiotics have been performed in patients
with stable or acute coronary heart disease on the
assumption that microorganisms, in particular Chla-
mydia pneumoniae, are implicated in atherosclerosis
initiation and progression (2).
Hence, it is methodologically inappropriate to
extrapolate from these ﬁndings that infections can-
not precipitate MI because these clinical settings are
different in terms of clinical course, concomitant
treatment, and very likely, mechanism of disease
from CAP-related MI. In this context, it is clinically
relevant that pneumonia severity score was a
strong predictor of MI, indicating that the severity of
infection and/or inﬂammation plays a key role in
favoring myocardial ischemia. Platelet activation
may be one mechanism through which CAP pre-
cipitates MI via a process of coronary thrombosis
and/or vasoconstriction. We don’t have conclusive
data on this issue, but it is interesting to underscorethat most patients with CAP disclosed non–ST-
segment elevation MI, indicating that type II MI and,
therefore, coronary vasoconstriction might have an
important role in favoring myocardial ischemia.
We agree with the authors that the concomitant
presence of cardiovascular disease or atherosclerotic
risk factors could account for platelet activation
detected at admission, but its signiﬁcant reduction,
observed at discharge, points to a role of CAP in
favoring platelet activation. The mechanism(s) ac-
counting for CAP-related platelet activation were not
investigated in the study and consequently may be
only a matter of speculation. Analysis of more
sophisticated markers of platelet activation will
certainly help to provide more insight into the role
of platelets as a determinant of myocardial ischemia
in pneumonia. However, we believe that at this
moment, it is more crucial to know whether platelet
activation represents a mere epiphenomenon of CAP
or has a role in triggering coronary thrombosis
and/or vasoconstriction. Thus, interventional trials
with aspirin or other antiplatelet drugs could be of
interest to investigate whether platelets actually
have a role in precipitating MI in patients with
pneumonia.
Interestingly, Dr. Khan and colleagues, in their
letter, suggest that statins may be an intriguing
alternative because they possess antiplatelet activity,
and a recent meta-analysis demonstrated a potential
role of statins in reducing CAP-related mortality (3).
We agree with this hypothesis because statins
disclose an early and late antiplatelet effect, which is
mediated by down-regulation of Nox2-derived
oxidative stress and lipid-lowering activity, respec-
tively (4). Nox2 down-regulation may be of interest
because in patients with CAP Nox2, the most
important cellular producer of oxygen free radicals,
is up-regulated and associated with myocardial
damage and ischemia (5). Furthermore, statins
amplify the platelet response to aspirin by reducing
platelet eicosanoid formation, namely isoprostanes
and thromboxane A2, and could, in turn, be useful in
case of incomplete COX1 inhibition by aspirin (4).
Hence, statins may be tested as an alternative to
aspirin or on top of aspirin to assess whether they
are able to reduce cardiac complications in patients
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